Clinical Evaluation of Tocilizumab Combined with Prednisone and Methotrexate in the Treatment of Refractory Moderate-To-Severe Rheumatoid Arthritis
Objective To investigate the clinical efficacy of tocilizumab combined with prednisone and methotrexate in the treatment of refractory moderate-to-severe rheumatoid arthritis(RA).Methods A total of 145 patients with refractory moderate-to-severe RA admitted to the hospital from March 2020 to March 2022 were selected and divided into the observation group(72 cases)and the control group(73 cases)by the stratified random method.The patients in the two groups were given Prednisone Acetate Tablets and Methotrexate Tablets orally,on this basis,the patients in the observation group were given the intravenous drip with Tocilizumab Injection.Both groups were treated continuously for three months.Results After treatment,the joint pain score and swelling score in the two groups significantly decreased,the duration of morning stiffness significantly shortened,the 28-joint Disease Activity Score(DAS-28)score significantly decreased,the Fugl-Meyer Motor Assessment(FMA)score significantly increased,the rheumatoid factor(RF),C-reactive protein(CRP)levels and erythrocyte sedimentation rate(ESR)significantly decreased,the matrix metalloproteinase-3(MMP-3)level significantly decreased,and the tissue inhibitor of metalloproteinase-1(TIMP-1)level significantly increased(P<0.05).Moreover,the above indexes improved more significantly in the observation group(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(11.11%vs.8.22%,P>0.05).Conclusion Tocilizumab combined with prednisone and methotrexate in the treatment of refractory moderate-to-severe RA can effectively relieve the symptoms of joint inflammation,decrease the serum inflammatory index levels,improve joint activity ability and joint injuries.
tocilizumabprednisonemethotrexaterefractoryrheumatoid arthritismoderate-to-severeinflammatory index
万方数据
维普
